DEXA-PSYCH Trial Investigates Dexamethasone as Rapid-Acting Depression Treatment
核心洞察
The DEXA-PSYCH study is testing dexamethasone, a synthetic glucocorticoid, as an add-on treatment for moderate-to-severe depression (搜索) in a 300-participant randomized controlled trial.
Previous meta-analysis data suggests glucocorticoids (搜索) may have larger effect sizes (SMD = 0.90) than current antidepressants (搜索) and could provide rapid symptom relief within 1-14 days.
The trial aims to address limitations of current depression (搜索) treatments, which show only small-to-moderate effects and often require 3-6 weeks to take effect, leaving patients at increased risk during the initial treatment period.
Researchers at the Mental Health Services in the Capital Region of Denmark (搜索) are launching the DEXA-PSYCH trial, a comprehensive study investigating whether dexamethasone, a widely available synthetic glucocorticoid, can provide rapid relief for patients with moderate-to-severe depression (搜索) when added to standard treatment.
The double-blind, placebo-controlled trial will enroll 300 participants with moderate-to-severe depression (搜索), randomizing them 1:1 to receive either dexamethasone or placebo as add-on therapy to their current antidepressant treatment. The intervention consists of oral dexamethasone at 4 mg daily for four days, followed by 2 mg daily for three days before discontinuation.
Addressing Critical Treatment Gaps
Depression (搜索) represents one of the leading causes of years lived with disability globally, yet current treatment options remain suboptimal. A recent large meta-analysis demonstrated that current antidepressant compounds achieve only small-to-moderate effect sizes, with tricyclic antidepressants (搜索) showing the largest effects at a standardized mean difference (SMD) of 0.48 compared to placebo.
"Clinical effects are often delayed until 3 to 6 weeks after treatment initiation, meanwhile leaving the patients at increased risk of, e.g., suicide," the researchers noted in their protocol. Additionally, reports suggest that one-third of patients do not achieve remission after treatment with at least two currently used antidepressant drugs.
Promising Preclinical Evidence
The rationale for investigating dexamethasone stems from mounting evidence linking inflammatory mechanisms to depression (搜索). A recent meta-analysis on anti-inflammatory agents in depression treatment found that these compounds achieved larger effect sizes (SMD = 0.64) than traditional antidepressants (搜索), while also improving response rates (rate ratio = 1.76) and remission rates (rate ratio = 2.14) compared to placebo.
Most notably, glucocorticoids (搜索) displayed the largest effect sizes among anti-inflammatory agents, "exceeding the effect sizes in reduction of depressive symptoms of the currently most effective anti-depressives by more than twofold (SMD = 0.90; 95% CI 0.36 to 1.44)." The effect on depressive symptoms was rapid, occurring in as little as 1 to 14 days.
However, the previous studies included only limited patient numbers (total n = 59, with 25 receiving glucocorticoid treatment) and followed patients for only up to 14 days, highlighting the need for larger, more comprehensive trials.
Trial Design and Methodology
The DEXA-PSYCH study addresses these limitations through rigorous methodology. Participants must be diagnosed with non-psychotic, moderate-to-severe depressive disorder according to ICD-10 criteria and score 22 or above on the 10-item Montgomery-Asberg Depression (搜索) Rating Scale (MADRS10) at baseline.
The primary outcome measures change from baseline on the MADRS10 at day 7, with follow-up assessments continuing through six months. Secondary outcomes include various depression (搜索) rating scales, anxiety measures, and comprehensive safety assessments using the Glucocorticoid Toxicity Index.
"The primary aim of the trial is to investigate if dexamethasone can cause a rapid improvement in symptoms and thus 'bridge' the effect until conventional anti-depressants have effect," the researchers explained.
Safety and Monitoring
Given the potential risks associated with glucocorticoid therapy, the trial includes extensive safety monitoring. Participants with contraindications to glucocorticoid treatment, including immunodeficiencies, active infections, diabetes mellitus, or prolonged QTc intervals, are excluded from participation.
Adverse events will be monitored from day 1 through day 10, covering the intervention period and potential withdrawal effects. The study employs app-based monitoring through the Monsenso platform to track adherence, adverse events, and daily symptom ratings.
Broader Implications
If successful, the trial could introduce the first new class of antidepressants (搜索) with a novel mechanism of action in decades. "The repurposing of existing medicine, in this case dexamethasone, can have a fast, positive impact on outcomes for patients," the researchers noted, emphasizing that dexamethasone is "a cheap, off-patent drug that can be readily employed for treatment in both low- and high-income countries."
The study also aims to investigate biomarkers that might predict treatment response, potentially enabling personalized treatment approaches based on inflammatory profiles.
Study Timeline and Recruitment
Participants are being recruited primarily through in- and outpatient services at the Mental Health Services in the Capital Region of Denmark (搜索), with additional recruitment from Mental Health Services in Region Zealand and private practitioners. The trial timeline includes baseline assessment, seven days of intervention, and follow-up assessments at 14 days, 28 days, and six months.
The DEXA-PSYCH trial represents the first clinical trial in 20 years to test glucocorticoids (搜索) for depression (搜索) treatment and will be the largest trial of its kind globally. Results are expected to provide definitive evidence on whether this approach can offer rapid relief for patients with moderate-to-severe depression (搜索) while maintaining acceptable safety profiles.